Skip to main content
Premium Trial:

Request an Annual Quote

In Silico: Feb 1, 2002

Premium

www.GenomeWeb.COM Daily

 

“We believe this is an ill-advised transaction for Pharmacopeia and have determined to vote all of the shares we control against the Eos acquisition.”

— Samuel Isaly, managing partner of OrbiMed

Find “Pharmacopeia Issues Plea to Block Shareholders’ Bid to Dash Eos Acquisition” by searching: Eos

 

Telescope for Sale

Taking advantage of its own broad computational technology and its proximity to genomics companies in the Bay Area, NASA Ames is striving to become NASA’s fundamental biology research hub. To beef up its internal genomics-oriented research projects, Ames researchers have been establishing working relationships with local genomics and proteomics companies and academic research centers.

 

Find “NASA Launches into Genome Space from Silicon Valley” by searching: NASA

War of Attrition

Former arch-enemies Affymetrix and Incyte Genomics have buried the legal hatchet, settling their four-year patent infringement battle and agreeing to cross-license the patents at issue. It’s somewhat of a Pyrrhic victory for Incyte, as it comes just seven weeks after it announced plans to exit the microarray manufacturing business and effectively removed itself as a direct competitor to Affy.

 

Find “Affymetrix and Incyte Settle Long-Standing Patent Suit” by searching: Pyrrhic

 

www.PROTEOMONITOR.COM WEEKLY

The Great ICAT Hope

When Applied Biosystems introduced a commercial version of the ICAT reagent technology last March, proteomics researchers had high hopes that it would provide a high-throughput alternative to 2D gel electrophoresis. Nine months later, however, only two companies engaged in industrial-scale proteomics — Celera Genomics and Oxford GlycoSciences — have fully adopted the technology.

 

Find “ICAT Slow to Catch On, But Is the Technology Too Promising to Pass Up?” by searching: ICAT

 

www.BIOINFORM.COM WEEKLY

All-Too-Standard Standards

When the Interoperable Informatics Infrastructure Consortium debuted, founding members promised an agile and swift alternative to the historically sluggish standardization process. But the I3C’s bylaws, expected in September, are still not in place. The bottleneck was finally broken in December, as members of the governance committee were able to reach agreement on some key issues.

 

Find “I3C Effort Picks Up Steam as Founding Members Reach Agreement on Intellectual Property Issues” by searching: I3C

 

www.BIOarraynews.COM WEEKLY

See Spot Dye

“When focusing on improving [microarray] technology, dyes are a good place to start. New dyes would be okay, but a deep understanding of the physics of the dyes would be more helpful, as sometimes the dyes interact with the specific clones. We see spots that are always green, no matter what.”

— Gary Churchill, staff scientist, Jackson Lab

Find “The Jackson Lab’s Gary Churchill on Sex, Flies, and Microarrays” by searching: Churchill